Skyrizi OverviewRisankizumab (trade name Skyrizi) is a humanized monoclonal antibody targeting interleukin 23A (IL-23A). Risankizumab is part of a collaboration between Boehringer Ingelheim and AbbVie. Risankizumab has been approved in Europe, USA, Canada and Japan for treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Contents 1 Clinical trials 1.1 Psoriasis 2 History 3 References 4 External links Clinical trials Psoriasis In a ...
Read more Skyrizi Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Risankizumab
Recent Skyrizi Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Injection: 75mg/0.83ml
NDC Database Records for Skyrizi: (1 result)Sorted by National Drug Code
- 0074-2042 SkyriziSkyrizi Kit by Abbvie Inc.